The information on this page is intended for healthcare professionals. Some of the products and services shown here may not be available in your country or region.
Feb. 24, 2022

MASTER DAPT Subclinical Study for High Bleeding Risk Patients

A considerable proportion of patients at high bleeding risk who undergo drug-eluting stent (DES) implantation are indicated for oral anticoagulation (OAC); however, the optimal duration of antiplatelet therapy after such procedures is yet to be established, especially in combination with OAC.

MASTER DAPT (MAnagement of high bleeding risk patients post bioresorbable polymer coated STEnt implantation with an abbReviated versus prolonged DAPT regimen) was an investigator‑initiated, randomised, open‑label trial conducted in patients at high bleeding risk after the implantation of an Ultimaster™/Ultimaster™ Tansei™ DES. The trial compared abbreviated (1 month) dual antiplatelet therapy (DAPT) with non-abbreviated (3–12 month) DAPT. The MASTER DAPT trial recruited patients at high bleeding risk regardless of clinical presentation, and is valuable to inform clinical practice.

To find out more about the study, visit the page below.

*MASTER DAPT study is sponsored by the European Cardiovascular Research Institute (ECRI, Rotterdam, The Netherlands) and supported with a restricted research grant by Terumo Europe. The study is managed by global CROs and a data management group (CERC, Paris, France; Cardialysis, Rotterdam, The Netherlands; CV quest. Co. Ltd., Tokyo, Japan and CTU, Bern, Switzerland).